Ablexis, LLC

Ablexis created and commercializes a better transgenic mouse platform for human therapeutic antibody discovery. Our AlivaMab Mouse technology is a unique, patented next generation transgenic mouse platform that dramatically improves upon other therapeutic antibody discovery platforms.

A majority of the world's top 15 pharmaceutical companies have licensed and use AlivaMab Mouse for antibody drug discovery. Together, with licensees at smaller public and private companies, AlivaMab Mouse is being used in labs at more than a dozen sites around the world.

In May 2018, Ablexis' founder and Deerfield Management founded AlivaMab Discovery Services, an independent contract research organization that provides antibody drug discovery services to industry and academia using the AlivaMab Mouse platform, thus expanding access to this unique technology. The AlivaMab Mouse platform has been validated by Ablexis and our partners for producing therapeutic antibody candidates with qualities that include:

• Antibodies against challenging targets including membrane multi-spanners • Meeting challenging design goals such as very low picomolar IC50 values • Large panels of mAbs with high sequence diversity • Large panels of mAbs with high epitope diversity • Successful formatting into bispecific antibodies and CAR-Ts • Favorable developability profiles